CSL Limited News - CSL

CSL to Buy Novartis Influenza-Vaccine Unit for $275 Million

By Rebecca Thurlow SYDNEY--Blood products and vaccine maker CSL Ltd. (CSL.AU) has agreed to buy Novartis AG's (NVS) influenza-vaccine business for...

bioCSL Inc. Completes 2014-15 Flu Season Shipment of AFLURIA®

Approximately 16.2 million doses were delivered to providers One of the first U.S. suppliers to complete 2014-2015 seasonal influenza...

Plasma Donors Recognized During International Plasma Awareness Week For Helping Save Lives

Plasma Donors Recognized During International Plasma Awareness Week For Helping Save Lives CSL Plasma center openings are on the rise, as is the...

CSL Behring Launches $450 Million Capacity Expansion To Meet Growing Need For Lifesaving, Life-improving Therapies

CSL Behring Launches $450 Million Capacity Expansion To Meet Growing Need For Lifesaving, Life-improving Therapies Company further increases...

CSL Behring Expands Manufacturing Facility In Kankakee, Illinois To Meet Patients' Growing Needs

CSL Behring Expands Manufacturing Facility In Kankakee, Illinois To Meet Patients' Growing Needs The 140,000-square foot expansion has received...

Early Diagnosis Of Children With Primary Immunodeficiencies Focus Of Nationwide Awareness Campaign For School Nurses

Early Diagnosis Of Children With Primary Immunodeficiencies Focus Of Nationwide Awareness Campaign For School Nurses CSL Behring Assists The...

FDA Approves Use of AFLURIA® Influenza Vaccine with PharmaJet’s Needle-Free Injector

Jet injector device delivers single dose of injectable flu vaccine without a needle PharmaJet® Inc., the developer of a needle-free...

bioCSL Inc. Launches AFLURIA® Shipping Campaign for 2014-2015 Seasonal Influenza

bioCSL Inc. to supply U.S. Market with 16.5 Million Doses Historical reliability, coupled with dedicated commercial and production...

CSL Behring Announces the 2014 Interlaken Leadership Awards Recipient

CSL Behring Announces the 2014 Interlaken Leadership Awards Recipient Interlaken Leadership Awards Program Supports Original Research in the...

CSL Behring Launches Hizentra® Co-Pay Relief Program

CSL Behring Launches Hizentra® Co-Pay Relief Program Eligible Participants to Receive Payment Assistance with Out-of-Pocket Costs Associated with...

New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumi...

New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumin (rIX-FP) Data...

CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development -- Leading-edge...

CSL Behring Continues Commitment to Donate Bleeding Disorder Medications to World Federation of Hemophilia

CSL Behring Continues Commitment to Donate Bleeding Disorder Medications to World Federation of Hemophilia Donated coagulation factor supports...

CSL Behring Launches My Access™ Cost Share Program during Hemophilia Awareness Month

CSL Behring Launches My Access™ Cost Share Program during Hemophilia Awareness Month My Access Offers Out-of-Pocket Payment Assistance to...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

CSL Limited (CSL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CSL News

CSL to Buy Novartis Influenza-Vaccine Unit for $275 Million

bioCSL Inc. Completes 2014-15 Flu Season Shipment of AFLURIA®

Plasma Donors Recognized During International Plasma Awareness Week For Helping Save Lives

CSL Behring Launches $450 Million Capacity Expansion To Meet Growing Need For Lifesaving, Life-improving Therapies

CSL Behring Expands Manufacturing Facility In Kankakee, Illinois To Meet Patients' Growing Needs

Early Diagnosis Of Children With Primary Immunodeficiencies Focus Of Nationwide Awareness Campaign For School Nurses

FDA Approves Use of AFLURIA® Influenza Vaccine with PharmaJet’s Needle-Free Injector

bioCSL Inc. Launches AFLURIA® Shipping Campaign for 2014-2015 Seasonal Influenza

CSL Behring Announces the 2014 Interlaken Leadership Awards Recipient

CSL Behring Launches Hizentra® Co-Pay Relief Program

New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumi...

CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

CSL Behring Continues Commitment to Donate Bleeding Disorder Medications to World Federation of Hemophilia

CSL Behring Launches My Access™ Cost Share Program during Hemophilia Awareness Month

CSL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

CSL Limited (CSL) News

CSL Limited (CSL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

CSL News

CSL to Buy Novartis Influenza-Vaccine Unit for $275 Million

bioCSL Inc. Completes 2014-15 Flu Season Shipment of AFLURIA®

Plasma Donors Recognized During International Plasma Awareness Week For Helping Save Lives

CSL Behring Launches $450 Million Capacity Expansion To Meet Growing Need For Lifesaving, Life-improving Therapies

CSL Behring Expands Manufacturing Facility In Kankakee, Illinois To Meet Patients' Growing Needs

Early Diagnosis Of Children With Primary Immunodeficiencies Focus Of Nationwide Awareness Campaign For School Nurses

FDA Approves Use of AFLURIA® Influenza Vaccine with PharmaJet’s Needle-Free Injector

bioCSL Inc. Launches AFLURIA® Shipping Campaign for 2014-2015 Seasonal Influenza

CSL Behring Announces the 2014 Interlaken Leadership Awards Recipient

CSL Behring Launches Hizentra® Co-Pay Relief Program

New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumi...

CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

CSL Behring Continues Commitment to Donate Bleeding Disorder Medications to World Federation of Hemophilia

CSL Behring Launches My Access™ Cost Share Program during Hemophilia Awareness Month

CSL Discussion

Your Recent History